RxDoctor Payments Data

Lisa Bledsoe, MD

Family Medicine · Wendell, NCNPI 1740267178

Payments from drug & device makers

$10,709in general payments, 2019–2025

Across 557 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Amgen$881
  • Lilly USA, LLC$832
  • Supernus Pharmaceuticals, Inc.$623
  • GSK$617
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,683100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,709 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$24,591
Medicare patients
110
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$76,008
OzempicSemaglutide49$57,125
FarxigaDapagliflozin Propanediol35$38,932
EliquisApixaban29$29,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$21,577
MounjaroTirzepatide18$20,601
TrulicityDulaglutide13$20,179
JanuviaSitagliptin Phosphate17$17,262
XareltoRivaroxaban12$7,637
Repatha SyringeEvolocumab13$7,012
MyrbetriqMirabegron13$6,362
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,913
Atorvastatin Calcium302$2,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,714
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$481$76,00866 claims
Novo NordiskOzempic$1,061$57,12549 claims
Lilly USA, LLCMounjaro, Trulicity$832$40,78031 claims
AstraZenecaFarxiga$443$38,93235 claims
PfizerEliquis$440$29,26829 claims
GSKTrelegy Ellipta, Shingrix$617$24,48935 claims
MerckJanuvia$149$17,26217 claims
Johnson & JohnsonXarelto$219$7,63712 claims
Astellas Pharma US IncMyrbetriq$47$6,36213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Wendell

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →